Complement Therapeutics in Autoimmune Disease

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Apr 20

PMID 31001274

Citations 34

Authors

Joshua M Thurman

Roshini Yapa

Affiliations

Soon will be listed here.

Abstract

Many autoimmune diseases are characterized by generation of autoantibodies that bind to host proteins or deposit within tissues as a component of immune complexes. The autoantibodies can activate the complement system, which can mediate tissue damage and trigger systemic inflammation. Complement inhibitory drugs may, therefore, be beneficial across a large number of different autoimmune diseases. Many new anti-complement drugs that target specific activation mechanisms or downstream activation fragments are in development. Based on the shared pathophysiology of autoimmune diseases, some of these complement inhibitory drugs may provide benefit across multiple different diseases. In some antibody-mediated autoimmune diseases, however, unique features of the autoantibodies, the target antigens, or the affected tissues may make it advantageous to block individual components or pathways of the complement system. This paper reviews the evidence that complement is involved in various autoimmune diseases, as well as the studies that have examined whether or not complement inhibitors are effective for treating these diseases.

Citing Articles

C3 deficiency promotes pulmonary inflammation in AT1R-induced mouse model for systemic sclerosis.

Yin J, Verschoor A, Yue X, Goldmann T, Heidecke H, Riemekasten G Front Immunol. 2024; 15:1491324.

PMID: 39737181 PMC: 11683138. DOI: 10.3389/fimmu.2024.1491324.

Immunoglobulin G and Complement as Major Players in the Neurodegeneration of Multiple Sclerosis.

Kennedy P, Fultz M, Phares J, Yu X Biomolecules. 2024; 14(10).

PMID: 39456143 PMC: 11506455. DOI: 10.3390/biom14101210.

Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment.

Gallwitz M, Lindqvist I, Mulder J, Rasmusson A, Larsson A, Husen E Mol Psychiatry. 2024; .

PMID: 39304742 DOI: 10.1038/s41380-024-02750-y.

The Crystal Structure of the Michaelis-Menten Complex of C1 Esterase Inhibitor and C1s Reveals Novel Insights into Complement Regulation.

Garrigues R, Garrison M, Garcia B J Immunol. 2024; 213(5):718-729.

PMID: 38995166 PMC: 11333171. DOI: 10.4049/jimmunol.2400194.

Elevated concentration of beta2-microglobulin among patients with carpal tunnel syndrome in the course of primary Sjögren syndrome - a prospective observational study on 50 patients.

Koscinska-Shukla I, Jaskolska M, Chylinska M, Jaskolski D, Sieminski M, Chmielewski M Rheumatol Int. 2024; 44(9):1739-1747.

PMID: 38969943 PMC: 11343790. DOI: 10.1007/s00296-024-05640-2.

References

Watanabe H, Garnier G, Circolo A, Wetsel R, Ruiz P, Holers V . Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol. 2000; 164(2):786-94. DOI: 10.4049/jimmunol.164.2.786. View

Hill G, Delahousse M, Nochy D, Remy P, Mignon F, Mery J . Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 2001; 59(1):304-16. DOI: 10.1046/j.1523-1755.2001.00492.x. View

Fishelson Z, Attali G, Mevorach D . Complement and apoptosis. Mol Immunol. 2001; 38(2-3):207-19. DOI: 10.1016/s0161-5890(01)00055-4. View

Einav S, Pozdnyakova O, Ma M, Carroll M . Complement C4 is protective for lupus disease independent of C3. J Immunol. 2002; 168(3):1036-41. DOI: 10.4049/jimmunol.168.3.1036. View

Mitchell D, Pickering M, Warren J, Fossati-Jimack L, Cortes-Hernandez J, Cook H . C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol. 2002; 168(5):2538-43. DOI: 10.4049/jimmunol.168.5.2538. View

Lucchinetti C, Mandler R, McGavern D, Bruck W, Gleich G, Ransohoff R . A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002; 125(Pt 7):1450-61. PMC: 5444467. DOI: 10.1093/brain/awf151. View

Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann J, Bensman A . Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002; 346(26):2053-60. DOI: 10.1056/NEJMoa012895. View

Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y . Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002; 110(7):955-63. PMC: 151154. DOI: 10.1172/JCI15918. View

Tuzun E, Scott B, Goluszko E, Higgs S, Christadoss P . Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol. 2003; 171(7):3847-54. DOI: 10.4049/jimmunol.171.7.3847. View

10.

Girardi G, Berman J, Redecha P, Spruce L, Thurman J, Kraus D . Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003; 112(11):1644-54. PMC: 281643. DOI: 10.1172/JCI18817. View

11.

Elliott M, Jarmi T, Ruiz P, Xu Y, Holers V, Gilkeson G . Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 2003; 65(1):129-38. DOI: 10.1111/j.1523-1755.2004.00371.x. View

12.

Haas M, Eustace J . Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int. 2004; 65(6):2145-52. DOI: 10.1111/j.1523-1755.2004.00632.x. View

13.

Rother R, Mojcik C, McCroskery E . Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus. 2004; 13(5):328-34. DOI: 10.1191/0961203303lu1021oa. View

14.

Thurman J, Kraus D, Girardi G, Hourcade D, Kang H, Royer P . A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2004; 42(1):87-97. DOI: 10.1016/j.molimm.2004.07.043. View

15.

Lennon V, Wingerchuk D, Kryzer T, Pittock S, Lucchinetti C, Fujihara K . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364(9451):2106-12. DOI: 10.1016/S0140-6736(04)17551-X. View

16.

Cunningham P, Quigg R . Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol. 2005; 16(5):1214-22. DOI: 10.1681/ASN.2005010096. View

17.

Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R . Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005; 106(7):2340-6. DOI: 10.1182/blood-2005-03-1319. View

18.

Bao L, Osawe I, Haas M, Quigg R . Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol. 2005; 175(3):1947-55. DOI: 10.4049/jimmunol.175.3.1947. View

19.

Bao L, Osawe I, Puri T, Lambris J, Haas M, Quigg R . C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol. 2005; 35(8):2496-506. DOI: 10.1002/eji.200526327. View

20.

Kaminski H, Kusner L, Richmonds C, Medof M, Lin F . Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol. 2006; 202(2):287-93. DOI: 10.1016/j.expneurol.2006.06.003. View